Table 2.
Current clinical trials involving ncRNAs.
| ncRNA | Study title | Condition or disease | Interventions | Primary purpose | Clinical trails identifier | Status |
|---|---|---|---|---|---|---|
| miR-16 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients with Recurrent MPM and NSCLC |
Mesothelioma Non-small cell lung cancer |
Drug: TargomiRs | Treatment | NCT02369198 | Completed |
| miR-34 | Critical Role of MicroRNA-34a and MicroRNA-194 in Acute Myeloid Leukemia With CEBPA Mutations | Leukemia | Genetic: RNA analysis | Not Reported | NCT01057199 | Completed |
| miR-29 | Phase 1: safety, tolerability and pharmacokinetic study of MRG-201 in healthy volunteers | Healthy volunteers | Drug: MRG-201 | Treatment | NCT02603224 | Completed |
| miR-155 | The Potential Role Of microRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation | Bladder cancer | Diagnostic test | Diagnostic | NCT03591367 | Completed |
| miR-221 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma | Hepatocellular carcinoma | Analysis of microRNA expression | Not Reported | NCT02928627 | Unknown |
| miRNA/lncRNA | Noncoding RNA in the exosome of the epithelial ovarian cancer | Ovarian cancer | Sequencing miRNA/lncRNA | NCT03738319 | Recruiting | |
| miRNA | Circulating miRNAs as biomarkers of hormone sensitivity in breast cancer | Breast cancer | Drugs: tamoxifen, letrozole, anastrozole, exemestane | Treatment | NCT01612871 | Completed |
| miRNA | Circulating microRNA as disease markers in pediatric cancer | Leukemia lymphoma | Not reported | Observational | NCT01541800 | Recruiting |
Source: ClinicalTrials.gov.